Cargando…

Predictors of the change in bilirubin levels over twelve weeks of treatment with atazanavir

Detalles Bibliográficos
Autores principales:	Cotter, Aoife G, Brown, Aisling, Sheehan, Gerard, Lambert, John, Sabin, Caroline A, Mallon, Patrick WG
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658904/ https://www.ncbi.nlm.nih.gov/pubmed/23680529 http://dx.doi.org/10.1186/1742-6405-10-13

Ejemplares similares

Seroprevalence of Schistosomiasis and Strongyloides infection in HIV-infected patients from endemic areas attending a European infectious diseases clinic
por: Sadlier, Corinna M, et al.
Publicado: (2013)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
por: Lozano, Roberto, et al.
Publicado: (2013)

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients
por: Rekić, Dinko, et al.
Publicado: (2012)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]
Publicado: (2013)

Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation
por: Leger, Paul, et al.
Publicado: (2018)

Assessment of trabecular bone score, an index of bone microarchitecture, in HIV positive and HIV negative persons within the HIV UPBEAT cohort
por: McGinty, Tara, et al.
Publicado: (2019)

Atazanavir nephrotoxicity
por: Hara, Masaki, et al.
Publicado: (2015)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
por: Samuel, Miriam, et al.
Publicado: (2014)

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
por: Else, LJ, et al.
Publicado: (2010)

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir
por: Robertson, Kevin, et al.
Publicado: (2018)

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
por: Ganesan, Anuradha, et al.
Publicado: (2009)

Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function
por: Guillemi, Silvia A, et al.
Publicado: (2016)

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
por: Smits, Mark M., et al.
Publicado: (2016)

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
por: Wiesmann, Frank, et al.
Publicado: (2011)

The ASSURE study: HIV‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir
por: Wohl, DA, et al.
Publicado: (2015)

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir
por: Jose, Sophie, et al.
Publicado: (2017)

Post-COVID care delivery: The experience from an Irish tertiary centre’s post-COVID clinic
por: Heeney, Aoife, et al.
Publicado: (2023)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
por: Overton, T, et al.
Publicado: (2010)

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
por: Squires, Kathleen E., et al.
Publicado: (2011)

Discovery and validation of serum biomarkers expressed over the first twelve weeks of Fasciola hepatica infection in sheep
por: Rioux, M.-C., et al.
Publicado: (2008)

Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks
por: Speer, Claudius, et al.
Publicado: (2021)

Incidence of atazanavir- associated adverse drug reactions in second -line drugs treated south Indian HIV-1 infected patients
por: Subashini, Dhakshinamoorthy, et al.
Publicado: (2016)

Role of atazanavir in the treatment of HIV infection
por: Rivas, Pablo, et al.
Publicado: (2009)

Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?
por: Gervasoni, Cristina, et al.
Publicado: (2015)

Antiretroviral regimen complexity as a predictor of adherence
por: Boyle, C, et al.
Publicado: (2010)

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial(§)
por: Gallant, Joel, et al.
Publicado: (2017)

Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination with a twelve-week interval
por: Sheng, Wang-Huei, et al.
Publicado: (2023)

Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir
por: Beckman, Joshua A., et al.
Publicado: (2017)

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks
por: Squires, Kathleen E, et al.
Publicado: (2017)

Interferon lambda rs368234815 ΔG/ΔG is associated with higher CD4(+):CD8(+) T-cell ratio in treated HIV-1 infection
por: Freitas, Inês T., et al.
Publicado: (2020)

A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi
por: Ongubo, Dennis Miyoge, et al.
Publicado: (2017)

A randomized, controlled study exploring factors associated with decision to undergo HIV screening
por: O’Connor, Gerard, et al.
Publicado: (2014)

Twelve Weeks of Yoga or Nutritional Advice for Centrally Obese Adult Females
por: Telles, Shirley, et al.
Publicado: (2018)

Ureteral Obstruction Due to Radiolucent Atazanavir Ureteral Stones
por: Grant, Michael T., et al.
Publicado: (2017)

Atazanavir Crystal–Induced Chronic Granulomatous Interstitial Nephritis
por: Varghese, Vipin, et al.
Publicado: (2020)

Atazanavir/efavirenz/lamivudine: Covid-19: case report
Publicado: (2021)

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations
por: Rhee, Soo-Yon, et al.
Publicado: (2022)

Orofacial findings in chronic granulomatous disease: report of twelve patients and review of the literature
por: Dar-Odeh, Najla S, et al.
Publicado: (2010)

A comparison trial of eight weeks versus twelve weeks of exercise program in interstitial lung diseases
por: Naz, Ilknur, et al.
Publicado: (2018)

Effect of bilirubin on cytochrome c oxidase activity of mitochondria from mouse brain and liver
por: Malik, Safarina G, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_8j3g1553n6m9kektdau29gt8i7